Patents by Inventor Todd Shearer

Todd Shearer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION FOR USE IN TREATING CANCERS
    Publication number: 20240122881
    Abstract: The present disclosure relates to methods of treating cancers comprising co-administration of mirdametinib (Compound A) or a pharmaceutically acceptable salt thereof, and 1-((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(2,4,5-trifluorophenyl) urea (Compound B) or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 18, 2024
    Inventor: Todd SHEARER
  • TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB
    Publication number: 20240058282
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 24, 2023
    Publication date: February 22, 2024
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • Mirdametinib treatment
    Patent number: 11883375
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: June 14, 2023
    Date of Patent: January 30, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • NON-LINEAR DOSING OF MIRDAMETINIB
    Publication number: 20240000731
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 4, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd SHEARER
  • Mirdametinib treatment
    Patent number: 11839595
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: December 12, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
    Patent number: 11819487
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 21, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Non-linear dosing of mirdametinib
    Patent number: 11806321
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Mirdametinib treatment
    Patent number: 11806322
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • MIRDAMETINIB TREATMENT
    Publication number: 20230321014
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 12, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • MIRDAMETINIB TREATMENT
    Publication number: 20230321013
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF 1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: March 16, 2023
    Publication date: October 12, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA WITH MIRDAMETINIB
    Publication number: 20230293464
    Abstract: The present disclosure relates to methods for treating pancreatic ductal adenocarcinoma comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Badreddin Edris, Collin Todd, Todd Shearer, Nenad Sarapa, Mary Smith
  • NON-LINEAR DOSING OF MIRDAMETINIB
    Publication number: 20230293462
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Shearer
  • MIRDAMETINIB TREATMENT
    Publication number: 20230293466
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: March 20, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB
    Publication number: 20230293472
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Uchenna H Iloejeo, Abraham J Langseth, Todd Shearer
  • TREATMENT OF OVARIAN CANCER WITH NIROGACESTAT
    Publication number: 20230241028
    Abstract: The present disclosure relates to methods for treating ovarian cancer comprising nirogacestat or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 1, 2023
    Publication date: August 3, 2023
    Inventors: Shinta CHENG, Todd SHEARER
  • Multiple event notification appliance
    Patent number: 8138928
    Abstract: An apparatus, system and method including an event notification appliance including first and second light sources configured to indicate an event, including a fire and/or alert.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: March 20, 2012
    Assignee: SimplexGrinnell LP
    Inventors: Daniel G. Farley, Todd Shearer, John Durst
  • Multiple Event Notification Appliance
    Publication number: 20100188234
    Abstract: An apparatus, system and method including an event notification appliance including first and second light sources configured to indicate an event, including a fire and/or alert.
    Type: Application
    Filed: January 27, 2009
    Publication date: July 29, 2010
    Applicant: SIMPLEXGRINNELL LP
    Inventors: Daniel Farley, Todd Shearer, John Durst